Literature DB >> 7869046

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.

L Llorente1, W Zou, Y Levy, Y Richaud-Patin, J Wijdenes, J Alcocer-Varela, B Morel-Fourrier, J C Brouet, D Alarcon-Segovia, P Galanaud, D Emilie.   

Abstract

Interleukin-10 (IL-10) is produced at a high level by B lymphocytes and monocytes of patients with systemic lupus erythematosus (SLE). In the present work, we analyzed whether this increased production of IL-10 contributed to the abnormal production of immunoglobulins (Ig) and of autoantibodies in SLE. The role of IL-10 was compared with that of IL-6, another cytokine suspected to play a role in these abnormalities. The spontaneous in vitro production of IgM, IgG, and IgA by peripheral blood mononuclear cells from SLE patients was weakly increased by recombinant IL (rIL)-6, but strongly by rIL-10. This production was not significantly affected by an anti-IL-6 mAb but was decreased by an anti-IL-10 mAb. We then tested the in vivo effect of these antibodies in severe combined immunodeficiency mice injected with PBMC from SLE patients. The anti-IL-6 mAb did not significantly affect the serum concentration of total human IgG and of anti-double-stranded DNA IgG in the mice. In contrast, the anti-IL-10 mAb strongly inhibited the production of autoantibodies, and, to a lesser extent, that of total human IgG. These results indicate that the Ig production by SLE B lymphocytes is largely IL-10 dependent, and that the increased production of IL-10 by SLE B lymphocytes and monocytes may represent a critical mechanism in the emergence of the autoimmune manifestations of the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7869046      PMCID: PMC2191898          DOI: 10.1084/jem.181.3.839

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

Review 1.  Lymphocyte biology in lupus.

Authors:  B S Handwerger
Journal:  Curr Opin Rheumatol       Date:  1990-10       Impact factor: 5.006

Review 2.  Cytokines from lymphoid organs of HIV-infected patients: production and role in the immune disequilibrium of the disease and in the development of B lymphomas.

Authors:  D Emilie; R Fior; L Llorente; A Marfaing-Koka; M Peuchmaur; O Devergne; B Jarrousse; J Wijdenes; F Boue; P Galanaud
Journal:  Immunol Rev       Date:  1994-08       Impact factor: 12.988

3.  Delayed hypersensitivity in systemic lupus erythematosus.

Authors:  S R Block; C B Gibbs; M B Stevens; L E Shulman
Journal:  Ann Rheum Dis       Date:  1968-07       Impact factor: 19.103

4.  Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10.

Authors:  A O'Garra; R Chang; N Go; R Hastings; G Haughton; M Howard
Journal:  Eur J Immunol       Date:  1992-03       Impact factor: 5.532

5.  In vivo production of interleukin-10 by malignant cells in AIDS lymphomas.

Authors:  D Emilie; R Touitou; M Raphael; M Peuchmaur; O Devergnee; D Rea; J Coumbraras; M C Crevon; L Edelman; I Joab
Journal:  Eur J Immunol       Date:  1992-11       Impact factor: 5.532

6.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

7.  Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices.

Authors:  J Guzmán; M H Cardiel; A Arce-Salinas; J Sánchez-Guerrero; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1992-10       Impact factor: 4.666

8.  A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody.

Authors:  C Morimoto; A D Steinberg; N L Letvin; M Hagan; T Takeuchi; J Daley; H Levine; S F Schlossman
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

9.  Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells.

Authors:  H Ishida; R Hastings; J Kearney; M Howard
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

10.  Systemic autoimmune disease arises from polyclonal B cell activation.

Authors:  D M Klinman; A D Steinberg
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

View more
  148 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

3.  Calorie restriction decreases proinflammatory cytokines and polymeric Ig receptor expression in the submandibular glands of autoimmune prone (NZB x NZW)F1 mice.

Authors:  A R Muthukumar; C A Jolly; K Zaman; G Fernandes
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

Review 4.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

5.  Interleukin-10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population.

Authors:  Milton O Moraes; Adalberto R Santos; Joris J M Schonkeren; Patrícia R Vanderborght; Tom H M Ottenhoff; Maria E Moraes; José R Moraes; Elizabeth P Sampaio; Euzenir N Sarno; Tom W J Huizinga
Journal:  Immunogenetics       Date:  2003-03-05       Impact factor: 2.846

6.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

7.  IVIg attenuates TLR-9 activation in B cells from SLE patients.

Authors:  Aharon Kessel; Regina Peri; Tharwat Haj; Ayelet Snir; Gleb Slobodin; Edmond Sabo; Itzhak Rosner; Yehuda Shoenfeld; Elias Toubi
Journal:  J Clin Immunol       Date:  2010-10-05       Impact factor: 8.317

8.  Interleukin-10 receptor expression and signalling were down-regulated in CD4⁺ T cells of lupus nephritis patients.

Authors:  H D Cui; Z M Qi; L L Yang; L Qi; N Zhang; X L Zhang; S Y Du; Y Jiang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

9.  VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus.

Authors:  Paolo Fagone; Karuppiah Muthumani; Katia Mangano; Gaetano Magro; Pier Luigi Meroni; Joseph J Kim; Niranjan Y Sardesai; David B Weiner; Ferdinando Nicoletti
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

10.  Endogenous IL-10 maintains immune tolerance but IL-10 gene transfer exacerbates autoimmune cholangitis.

Authors:  Yu-Hsin Hsueh; Hung-Wen Chen; Bi-Jhen Syu; Chia-I Lin; Patrick S C Leung; M Eric Gershwin; Ya-Hui Chuang
Journal:  J Autoimmun       Date:  2018-09-28       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.